<< Colchicine Dosage

Colchicine Side Effects >>

Colchicine FDA

June 10, 2011 by Lynn.

Colchicine and FDA

The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication's active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale).

Colchicine has been used by healthcare practitioners for many years to treat gout but had not been approved by the FDA. The FDA has an initiative underway to bring unapproved, marketed products like colchicine under its regulatory framework. This initiative promotes the goal of assuring that all marketed drugs meet modern standards for safety, effectiveness, quality and labeling.

Physicians historically have given colchicine hourly for acute gout flares until the flare subsided or they had to stop treatment because the patient began experiencing gastrointestinal problems. A dosing study required as part of FDA approval demonstrated that one dose initially and a single additional dose after one hour was just as effective as continued hourly dosing for acute gout flares, but much less toxic. As a result, the drug is being approved for acute gout flares with the lower recommended dosing regimen.

The FDA is alerting healthcare professionals to this new dosing regimen and also warning about the potential for severe drug interactions when patients take colchicine.

Read the full article FDA Approves Colchicine for Acute Gout, Mediterranean Fever from FDA Press Announcements.

Filed under: Colchicine FDA.

Tags: colchicine fda, colcrys fda, fda approved, colchicine, colcrys approval, colchicine for gout, colchicine information.


Gracelyn says at 2012-04-13 11:04:40:

I found just what I was needed, and it was etenritaning!

Leave your comment:

Name (required, limit 30 characters):
Email (required, will not be published):
Your Comment:
Veri Code (not case-sensitive):
Most Recent Posts